Preparation method of fluorescence probe for plasma enhanced fluorescence and application of fluorescence probe for detecting beta-amyloid protein
Through plasma enhanced fluorescence technology combined with BODIPY fluorescence probe, gold nanoparticles and silica encapsulated layer enhance the fluorescence signal, solving the signal specificity and stability problems in β-amyloid detection, achieving high sensitivity and accuracy The test is suitable for the early diagnosis of Alzheimer's disease.
Patent Information
- Application Number
- CN202411190289.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-28
- Publication Date
- 2024-12-06
AI Technical Summary
The prior art has problems such as poor signal specificity, low fluorescence dye stability, low fluorescence yield, complex detection process, expensive instrument dependence and large environmental interference when detecting β-amyloid, especially in the early stages of Alzheimer's disease. Sensitive and rapid detection is difficult to achieve in diagnosis.
Using plasma enhanced fluorescence technology combined with BODIPY fluorescence probe, the enhancement of fluorescence signal is controlled through gold nanoparticles and silica encapsulation layer, and a plasma enhanced fluorescence probe Au NPs@SiO2-BODIPY is designed to improve the fluorescence intensity and have time and pH. Stability, used for quantitative detection of β-amyloid and live cell fluorescence imaging.
Achieve high sensitivity detection of β-amyloid, enhance fluorescence signals, improve detection specificity and accuracy, simplify operation, reduce dependence on expensive instruments, and maintain good stability in biological environments and cell activity.
Smart Images

Figure CN119081682A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of fluorescent probes, and in particular relates to a method for preparing a fluorescent probe of plasma enhanced fluorescence and an application of the fluorescent probe in the detection of beta-amyloid protein. Background Art
[0002] Alzheimer's disease (AD) is an irreversible neurodegenerative disease with clinical manifestations of cognitive, dementia, and memory loss. The pathomorphological hallmarks of the pathogenesis of AD are believed to be the gradual accumulation of Aβ peptides Aβ1-40 (Aβ40) and Aβ1-42 (Aβ42) to form amyloid plaques, and neurofibrillary tangles in neurons containing hyperphosphorylated Tau protein. The final diagnosis of AD is based on postmortem histopathological detection of neurofibrillary tangles and amyloid plaques in brain tissue. Therefore, a more sensitive method is needed to detect the misfolding and aggregation of β-amyloid protein at an early stage, especially before the patient's condition progresses to Alzheimer's disease, and to visualize this process to assess the status of the disease.
[0003] At present, the imaging techniques of amyloid include positron emission tomography, magnetic resonance imaging, single photon emission computed tomography, and fluorescence imaging of fluorescent dyes (such as thioflavin S, thioflavin T, and Congo red). However, the high cost and dangerous ionizing radiation limit the application of scanning imaging. In addition, due to the small specific difference between aggregates and surrounding tissues, the sensitivity of magnetic resonance imaging is low. The key to forming imaging with high contrast and high sensitivity under background and aggregation-related signals is that the fluorescent probe can specifically enhance the signal of amyloid plaques. Conventional fluorescent dyes for imaging of β-amyloid often have low stability and low fluorescence yield, which limits their further targeting of β-amyloid in vivo. Therefore, it is very necessary to design a plasmon fluorescence enhancement probe for detecting β-amyloid to achieve more sensitive and rapid detection. However, there are few reports on combining BODIPY-based probes with plasmon fluorescence enhancement for detecting β-amyloid. Summary of the invention
[0004] Purpose of the invention: In view of the problems existing in the prior art, the present invention provides a method for preparing a fluorescent probe of plasma-enhanced fluorescence. The fluorescent probe prepared by the present invention improves the luminescence intensity of the BODIPY fluorescent probe for the first time through plasma-enhanced fluorescence technology, and has good time and pH stability and biocompatibility, and can be used as a specific β-amyloid protein concentration indicator. In addition, its preparation process is simple, which can effectively solve the shortcomings of the existing β-amyloid protein detection, such as complex operation, expensive instruments or large environmental interference.
[0005] The invention also provides the prepared fluorescent probe and its application in quantitative detection of beta-amyloid protein and fluorescent imaging of living cells.
[0006] Technical solution: In order to achieve the above-mentioned purpose, the preparation method of a fluorescent probe for plasma enhanced fluorescence described in the present invention comprises the following steps:
[0007] (1) 4-carboxybenzaldehyde, 2,4-dimethylpyrrole, trifluoroacetic acid, tetrachlorobenzoquinone, triethylamine, and boron trifluoride etherate are mixed and reacted to prepare the fluorescent probe BODIPY;
[0008] (2) adding sodium citrate to a chloroauric acid solution to react and prepare a gold nanoparticle (Au NPs) solution;
[0009] (3) reacting an organic solvent, ammonia water and tetraethyl orthosilicate in the gold nanoparticle solution to obtain a gold nanoparticle solution coated with silicon dioxide;
[0010] (4) reacting (3-aminopropyl)trimethoxysilane with a solution of gold nanoparticles coated with silica to obtain an amino-modified solution of silicon-coated gold nanoparticles;
[0011] (5) The BODIPY fluorescent probe, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N-hydroxysuccinimide and amino-modified silicon-coated gold nanoparticle solution were reacted to prepare the plasmon-enhanced fluorescent probe Au NPs@SiO2-BODIPY.
[0012] In step (1), 4-carboxybenzaldehyde is dissolved in dichloromethane, and then 2,4-dimethylpyrrole is added and trifluoroacetic acid is added dropwise to the mixed solution, and stirred at room temperature for 10-14 hours, and then tetrachlorobenzoquinone is added to react for 4-6 hours, and then triethylamine is added to react for 20-40 minutes, and finally boron trifluoride etherate is added, and stirred at room temperature overnight. The product is purified by chromatography on a silica gel column to obtain a solid powder of the fluorescent probe BODIPY.
[0013] Preferably, in step (1), 4-carboxybenzaldehyde is dissolved in dichloromethane, and then 2,4-dimethylpyrrole is added and trifluoroacetic acid is added dropwise to the mixed solution, and stirred at room temperature for 12 hours, and then tetrachlorobenzoquinone is added to react for 5 hours, and then triethylamine is added to react for 30 minutes, and finally boron trifluoride etherate is added, and stirred at room temperature overnight. The product is purified by chromatography on a silica gel column to obtain a solid powder of the fluorescent probe BODIPY.
[0014] Wherein, in step (1), the molar ratio of 4-carboxybenzaldehyde, 2,4-dimethylpyrrole and tetrachlorobenzoquinone is 1-2:2-4:1-2; the volume ratio of dichloromethane, triethylamine and boron trifluoride etherate is 3-12:1:1; and the amount of trifluoroacetic acid added is 1-4 drops.
[0015] Preferably, in step (1), the molar ratio of 4-carboxybenzaldehyde, 2,4-dimethylpyrrole and tetrachlorobenzoquinone is 1:2:1; the volume ratio of dichloromethane, triethylamine and boron trifluoride etherate is 10:1:1; and the amount of trifluoroacetic acid added is 3-4 drops.
[0016] In step (2), after the chloroauric acid aqueous solution is heated to boiling, a sodium citrate solution is added to react, and the solution is allowed to turn into wine red and then continued to boil for 3-7 minutes. After the solution is cooled, a gold nanoparticle solution is obtained.
[0017] Preferably, in step (2), after the chloroauric acid aqueous solution is heated to boiling, a sodium citrate solution is added to react, and the solution is allowed to turn wine red and then continued to boil for 5 minutes. After the solution is cooled, a gold nanoparticle solution is obtained.
[0018] Wherein, in step (2), the mass ratio of chloroauric acid to sodium citrate is 1:1-10.
[0019] Preferably, in step (2), the mass ratio of chloroauric acid to sodium citrate is 1:1.
[0020] In step (3), anhydrous ethanol and ammonia water are added to the gold nanoparticle solution, and then the ethyl orthosilicate solution is added to continue to react at room temperature for 6-24 hours to obtain a gold nanoparticle solution coated with silica.
[0021] Preferably, in step (3), anhydrous ethanol and aqueous ammonia are added to the gold nanoparticle solution, and then the ethyl orthosilicate solution is added to continue the reaction for 12 hours to obtain a solution of gold nanoparticles coated with silica.
[0022] Wherein, in step (3), the volume ratio of the gold nanoparticle solution, anhydrous ethanol, ammonia water and tetraethyl orthosilicate is 100:100-300:3-10:4-12.
[0023] Preferably, in step (3), the volume ratio of the gold nanoparticle solution, anhydrous ethanol, aqueous ammonia and tetraethyl orthosilicate is 100:200:7:6.
[0024] Wherein, in step (4), (3-aminopropyl)trimethoxysilane and the silicon-coated gold nanoparticle solution are reacted at 30-40° C. for 3-7 hours, and then reacted at 40-60° C. for 1-2 hours to obtain an amino-modified silicon-coated gold nanoparticle solution.
[0025] Preferably, in step (4), (3-aminopropyl)trimethoxysilane and the silicon-coated gold nanoparticle solution are reacted at 37° C. for 5 h, and then at 50° C. for 1 h to obtain an amino-modified silicon-coated gold nanoparticle solution.
[0026] Wherein, in step (4), the volume ratio of (3-aminopropyl)trimethoxysilane to the silicon-coated gold nanoparticle solution is 1-3:10.
[0027] Preferably, in step (4), the volume ratio of (3-aminopropyl)trimethoxysilane to the silicon-coated gold nanoparticle solution is 1:10.
[0028] In step (5), the BODIPY solution and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride are mixed and stirred at room temperature for 5-15 minutes, then N-hydroxysuccinimide is added to the mixed solution and stirred at room temperature for 10-30 minutes, and finally the amino-modified silicon-coated gold nanoparticle solution is added and stirred at room temperature for 3-5 hours to obtain the plasmon-enhanced fluorescent probe Au NPs@SiO2-BODIPY.
[0029] Preferably, in step (5), the BODIPY solution and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride are mixed and stirred for 10 minutes, then N-hydroxysuccinimide is added to the mixed solution and stirred for 20 minutes, and finally the amino-modified silicon-coated gold nanoparticle solution is added and stirred for 4 hours to obtain the plasmon-enhanced fluorescent probe Au NPs@SiO2-BODIPY.
[0030] Wherein, in step (5), the molar ratio of BODIPY solution, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N-hydroxysuccinimide, and amino-modified silicon-coated gold nanoparticle solution is 0.2-1:300-900:300-900:1.
[0031] Preferably, in step (5), the molar ratio of BODIPY solution, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N-hydroxysuccinimide, and amino-modified silicon-coated gold nanoparticle solution is 0.33:600:600:1.
[0032] The plasma enhanced fluorescence fluorescent probe prepared by the preparation method of the present invention.
[0033] Application of the fluorescent probe prepared by the preparation method of the present invention in quantitative detection of beta-amyloid protein.
[0034] The fluorescent probe prepared by the preparation method of the present invention is used for quantitatively detecting beta-amyloid protein in living cells.
[0035] Preferably, the plasma enhanced fluorescence fluorescent probe prepared by the present invention can be used for quantitative detection of β-amyloid protein and application in fluorescence imaging of CT26 and PAN02 cells.
[0036] The fluorescent probe of the present invention is used in preparing reagents or tools for quantitative detection of beta-amyloid protein and cell fluorescence imaging.
[0037] The present invention combines the plasma enhanced fluorescence technology with the fluorescent probe BODIPY for the first time and applies it to the detection of β-amyloid protein. Plasmon-enhanced fluorescence (PEF) is a phenomenon in which a fluorescent emitter is combined with the localized surface plasmon resonance (LSPR) near a metal nanostructure, and a new photon-driven process is used to significantly improve the light signal. The amplification of the fluorescence signal makes it possible to further apply weak fluorophores with low photostability. Based on PEF, people have designed a variety of fluorescent probes to improve the signal-to-noise ratio, such as detecting low-abundance miRNA-21 and interleukin-6, and highly sensitive fluorescent probes can be obtained. This fluorescence enhancement can be achieved by adjusting factors such as the shape, size, spacing and spectral overlap between the LSPR band and the emission / excitation wavelength.
[0038] The present invention prepares a protein aggregate fluorescence detection system based on plasma enhanced fluorescence. Au NPs and BODIPY are used as plasma enhanced nanoparticles and fluorescent groups, respectively. The distance between Au NPs and BODIPY is controlled by the silica shell to obtain the optimal silica shell thickness and density. The BODIPY fluorescent group is covalently bound to Au NPs@SiO2-NH2 to achieve fluorescence enhancement. The maximum fluorescence enhancement is obtained by controlling and optimizing the ratio of Au NPs to ethyl orthosilicate, BODIPY to Au NPs, and EDC to NHS, with an enhancement factor of 13 times.
[0039] The plasma fluorescence enhanced fluorescent probe prepared by the present invention is used for quantitative detection of β-amyloid protein and fluorescent imaging of living cells. Conventional fluorescent dyes often have low stability and low fluorescence yield for imaging of β-amyloid protein, which limits their further targeting of β-amyloid protein in vivo. BODIPY fluorescent probe has a high biological binding degree to β-amyloid protein and can be targeted and bound within the β-pleated sheet of β-amyloid protein, thereby improving the specificity of biological detection. This probe uses Au NPs to greatly enhance the fluorescence intensity of BODIPY, and can pass through the blood-brain barrier, thus solving the shortcomings of conventional fluorescent dyes such as high background fluorescence interference, poor tissue penetration, and poor biocompatibility.
[0040] The present invention successfully synthesized a boron dipyrrole (BODIPY) modified probe based on plasma enhanced fluorescence for detecting β-amyloid aggregates. Gold nanoparticles and BODIPY act as plasma and fluorescent substances, respectively. At the same time, the distance between Au NPs and BODIPY is controlled by the silica layer. Compared with the original BODIPY, the fluorescence signal of the BODIPY-modified plasma fluorescence enhanced fluorescent probe Au NPs@SiO2-BODIPY is enhanced by 13 times. 3D-FDTD results show that the signal amplification is due to the increase in electric field strength (3.78V / m). Aβ 42 The linear range and detection limit of the probe were 5-60 μM and 0.85 μM, respectively. The probe was used for the selective and sensitive identification of aβ aggregates in mouse colorectal cancer cells (CT26) and mouse pancreatic cancer cells (PAN02), and also showed higher fluorescence signals than the original BODIPY. This method has broad application prospects in the prediction and detection of neurodegenerative diseases.
[0041] This paper combines plasma enhanced fluorescence technology with fluorescent probe BODIPY for the first time and applies it to the detection of β-amyloid protein. By optimizing the shell thickness and controlling the distance, the maximum fluorescence enhancement is obtained, with an enhancement multiple of 13 times. 42 The effect is significant.
[0042] Beneficial effects: Compared with the prior art, the present invention has the following advantages:
[0043] 1. The preparation method of the plasma fluorescence enhanced fluorescent probe prepared by the present invention is simple and rapid, has basic requirements on instruments and technology, and is easy to mass produce.
[0044] 2. The plasma fluorescence enhanced fluorescent probe prepared by the present invention is based on the plasma fluorescence enhancement effect. The distance between BODIPY and the plasmon is controlled by the silicon dioxide layer to achieve the maximum fluorescence enhancement of the dye, thereby improving the stability of the fluorescent probe.
[0045] 3. The plasma fluorescence enhanced fluorescent probe prepared by the present invention uses the fluorescent probe BODIPY to turn on the response fluorescence of β-amyloid protein, and other protein analogs in the body (acetylcholinesterase, Na + , tyrosine, D-proline, L-glutamic acid, D-glucose, D-threonine, L-tryptophan, cysteine) had no obvious response effect, with strong specificity and high detection accuracy.
[0046] 4. The plasma fluorescence enhanced fluorescent probe prepared by the present invention can accurately detect the folding aggregation state and concentration of β-amyloid protein and produce changes in fluorescence signals accordingly. Its fluorescence intensity has a linear response between 5-60 μM and the detection limit is 0.85 μM.
[0047] 5. The plasma fluorescence enhanced fluorescent probe prepared by the present invention has high cell activity between 0-10 μM, indicating good biocompatibility and can realize fluorescence imaging of β-amyloid protein in living cells, which is of great significance for the prevention and early diagnosis of Alzheimer's disease. BRIEF DESCRIPTION OF THE DRAWINGS
[0048] Figure 1 The change of fluorescence intensity of the BODIPY solution prepared by the present invention with the change of water content;
[0049] Figure 2 The fluorescence excitation (a) and emission (b) spectra of BODIPY prepared in the present invention and the overlapping diagram of the UV-visible absorption spectra of Au NPs (c) and Au NPs@SiO2 (d);
[0050] Figure 3 This is an electric field simulation diagram of the gold nanoparticles prepared by the present invention;
[0051] Figure 4 This is a transmission electron microscopy image of Au NPs@SiO2 prepared in the present invention;
[0052] Figure 5 The plasma fluorescence enhancement factor diagram of different silicon dioxide layer thicknesses prepared by the present invention;
[0053] Figure 6 Fluorescence emission spectra of the BODIPY solution (a) and the plasma fluorescence enhanced fluorescent probe Au NPs@SiO2-BODIPY (b) prepared in the present invention;
[0054] Figure 7 Zeta potential diagrams of Au NPs (a), Au NPs@SiO2 (b), Au NPs@SiO2-NH2 (c), BODIPY (d), and Au NPs@SiO2-BODIPY (e) prepared in the present invention;
[0055] Figure 8 Infrared spectra of Au NPs (a), Au NPs@SiO2 (b), Au NPs@SiO2-NH2 (c), BODIPY (d), and Au NPs@SiO2-BODIPY (e) prepared in the present invention;
[0056] Fig. 9 Fluorescence lifetime diagrams of the BODIPY solution (a) and the plasma fluorescence enhanced fluorescent probe Au NPs@SiO2-BODIPY (b) prepared in the present invention;
[0057] Fig.10This is a fluorescence intensity stability test diagram of the plasma fluorescence enhanced fluorescence probe Au NPs@SiO2-BODIPY prepared by the present invention at different pH values;
[0058] Fig.11 The fluorescence intensity stability detection diagram of the plasma fluorescence enhanced fluorescent probe Au NPs@SiO2-BODIPY (a) and BODIPY solution (b) prepared by the present invention at different times;
[0059] Fig.12 The fluorescence changes of the BODIPY solution and the plasma fluorescence enhanced fluorescence probe Au NPs@SiO2-BODIPY prepared by the present invention and β-amyloid protein at different temperatures respectively;
[0060] Fig.13 The changes in fluorescence intensity (a) and absorbance (b) of the plasma fluorescence enhanced fluorescent probe Au NPs@SiO2-BODIPY prepared by the present invention and β-amyloid protein at 59°C over time;
[0061] Fig.14 The linear fitting diagram of the plasma fluorescence enhanced fluorescent probe Au NPs@SiO2-BODIPY prepared by the present invention and β-amyloid protein;
[0062] Fig.15 The fluorescence response diagram of the plasma fluorescence enhanced fluorescent probe Au NPs@SiO2-BODIPY prepared by the present invention and other interferences;
[0063] Fig.16 The cytotoxicity diagram of BODIPY solutions of different concentrations and the plasma fluorescence enhanced fluorescent probe Au NPs@SiO2-BODIPY prepared by the present invention in CT26 cells;
[0064] Fig.17 These are laser confocal fluorescence imaging images of the BODIPY solution prepared by the present invention and the plasma fluorescence enhanced fluorescent probe Au NPs@SiO2-BODIPY in CT26 and PAN02 cells. DETAILED DESCRIPTION
[0065] The present invention can be better understood according to the following examples. However, it is easy for those skilled in the art to understand that the contents described in the examples are only used to illustrate the present invention, and should not and will not limit the present invention described in detail in the claims.
[0066] The experimental methods described in the examples are conventional methods unless otherwise specified; the reagents and materials described are commercially available unless otherwise specified.
[0067] Among them, the β-amyloid protein powder was purchased from Shanghai MacLean Co., Ltd., human Aβ42, 95%, CAS number 107761-42-2, and item number A834109. The β-amyloid proteins used in the examples are all the above proteins.
[0068] Example 1
[0069] The preparation of a fluorescent probe for detecting β-amyloid protein comprises the following steps:
[0070] 1. Preparation of fluorescent probe BODIPY
[0071] 4-Carboxybenzaldehyde (1.00g, 0.0067mol) was placed in a 500mL round-bottom flask and dissolved in 100mL dichloromethane. Then 2,4-dimethylpyrrole (1.3mL, 0.0147mol) was added and 3 drops of trifluoroacetic acid were added to the mixed solution. During this process, an obvious color change was observed, from milky white to brownish yellow. The reactants were stirred at room temperature for 12h, followed by the addition of tetrachlorobenzoquinone (1.64g, 0.0067mol) for 5h. Then 10mL of triethylamine was added for 30min, and finally 10mL of etherified boron trifluoride was slowly and uniformly added, and stirred at room temperature overnight. The product was purified by chromatography on a silica gel column (petroleum ether: ethyl acetate = 1:9) to obtain a pink solid powder with green fluorescence, that is, the fluorescent probe BODIPY was obtained, and the structure is shown below.
[0072] BODIPY powder was dissolved in anhydrous ethanol to obtain a BODIPY solution (5 mM).
[0073]
[0074] 1 H NMR (600MHz, DMSO-d6): δ 8.09 (s, 2H), 7.46 (s, 2H), 6.19 (s, 2H), 2.45 (s, 9H), 1.23 (s, 3H).
[0075] 2. Preparation of gold nanoparticle solution
[0076] After heating the chloroauric acid aqueous solution (41 mL, mass fraction 0.01%) to boiling, sodium citrate solution (0.41 mL, mass fraction 1%) was added to continue the reaction. After about 1 minute, the solution changed from colorless to wine red and continued to boil for 5 minutes. After the solution was cooled, a gold nanoparticle solution (Au NPs) was obtained.
[0077] 3. Preparation of Silicon-coated Gold Nanoparticle Solution
[0078] Add 10 mL of anhydrous ethanol and 0.35 mL of ammonia water (25%) to 5 mL of gold nanoparticle solution and place it in a 50 mL round-bottom flask, then add ethyl orthosilicate solution (ethanol dissolved, 0.3 mL, 10 mM) and continue to react at room temperature for 12 hours to obtain a silica-coated gold nanoparticle solution (Au NPs@SiO2).
[0079] 4. Preparation of amino-modified silicon-coated gold nanoparticle solution
[0080] (3-Aminopropyl)trimethoxysilane (0.5 mL, 0.2 mM) and 5 mL of silica-coated gold nanoparticle solution were reacted at 37 °C for 5 h and then at 50 °C for 1 h to obtain amino-modified silica-coated gold nanoparticle solution (AuNPs@SiO2-NH2).
[0081] 5. Preparation of fluorescent probes
[0082] BODIPY solution (66.7 μL, 0.752 μM) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.0115 g) were mixed and stirred at room temperature for 10 min, then N-hydroxysuccinimide (0.0069 g) was added to the mixed solution and stirred at room temperature for 20 min, finally 5 mL of amino-modified silicon-coated gold nanoparticle solution was added and stirred at room temperature for 4 h to obtain a plasmon-enhanced fluorescent probe (Au NPs@SiO2-BODIPY).
[0083] Example 2
[0084] Changes in fluorescence intensity of the BODIPY solution prepared in Example 1 as the water content changes.
[0085] The BODIPY solution prepared in Example 1 was mixed with ethanol / water solutions with different water contents (0%-90%), and the fluorescence intensity was detected, wherein the final concentration of BODIPY was 20 μM.
[0086] Fluorescence spectrum test: Test the fluorescence spectrum of the above solution. The fluorescence excitation and emission spectrum is made with an excitation wavelength of 480nm, and the slit width of excitation and emission is 5nm / 5nm. The fluorescence intensity peaks of different solutions are taken to make fluorescence response graphs. The obtained fluorescence spectrum is shown in Figure 1 , indicating that as the water content increases, the fluorescence intensity of the fluorescent probe BODIPY gradually decreases.
[0087] Example 3
[0088] Overlapping graph of the fluorescence excitation and emission spectra of the BODIPY solution prepared in Example 1 and the UV-visible absorption spectra of the Au NPs solution and the Au NPs@SiO2 solution.
[0089] 1 mL of the BODIPY solution, Au NPs solution and Au NPs@SiO2 solution prepared in Example 1 were taken respectively.
[0090] Fluorescence spectrum test: Test the fluorescence excitation and emission spectra of the above solution. The fluorescence excitation and emission spectra are scanned in the wavelength range of 400-650nm with an excitation wavelength of 480nm and a slit width of 5nm / 5nm for excitation and emission. The obtained fluorescence excitation and emission spectra are shown in Figure 2 From curve a, we can see that the maximum excitation wavelength of BODIPY is at 480nm and the maximum emission wavelength is at 510nm.
[0091] UV-Visible absorption spectrum test: Test the UV-Visible absorption spectrum of the above solution. The UV-Visible absorption spectrum uses pure water as the reference solution and scans the spectrum in the wavelength range of 400-650nm. The obtained UV-Visible absorption spectrum is shown in Figure 2 From curve c, we can see that the maximum absorption wavelengths of Au NPs solution and Au NPs@SiO2 solution are both at 530nm, and the absorption peaks are stronger than Figure 2 Curve d of Au NPs@SiO2 solution, indicating the successful synthesis of Au NPs solution and Au NPs@SiO2 solution.
[0092] The fluorescence excitation and emission spectra of BODIPY solution ( Figure 2 Curves a, b) and UV-visible absorption spectra of Au NPs solution and Au NPs@SiO2 solution ( Figure 2 Curves c and d) are combined to obtain the spectral overlap diagram (see Figure 2 ). Figure 2 It shows that the UV absorption peak and the fluorescence emission peak partially overlap, indicating that in theory, the Au NPs solution and BODIPY have a plasmon fluorescence enhancement effect.
[0093] Example 4
[0094] Electric field simulation diagram of the gold nanoparticles prepared in Example 1.
[0095] The electric field intensity around the gold nanoparticles prepared in Example 1 was simulated using 3D-FDTD software. The resulting electric field simulation diagram is shown in Figure 3 , Figure 3 It shows that the maximum field strength around the gold nanoparticles is 3.78 V / m, indicating that the high electric field of the gold nanoparticles can produce an enhanced signal for BODIPY and compete with the quenching effect.
[0096] Example 5
[0097] Transmission electron microscopy image of Au NPs@SiO2 prepared in Example 1.
[0098] The copper mesh was immersed in the Au NPs@SiO2 solution, taken out, and placed on filter paper to dry. The sample on the copper mesh was observed and imaged using a transmission electron microscope. The transmission electron microscope image taken is shown in Figure 4 , Figure 4 The Au NPs were shown to be spherical in morphology with a particle size of about 39 nm and a layer of silicon dioxide coated on the surface with a thickness of about 6 nm, indicating the successful synthesis of Au NPs@SiO2.
[0099] Example 6
[0100] The plasma enhanced fluorescent probe Au NPs@SiO2-BODIPY solution prepared in Example 1 was subjected to optimization of synthesis parameters and a line graph of fluorescence enhancement multiples when the thickness of the silicon dioxide layer was optimized.
[0101] According to the method of Example 1, the synthesis parameters of Au NPs@SiO2-BODIPY solution with tetraethyl orthosilicate as silicon source were optimized, and the corresponding fluorescence enhancement multiples were detected for comparison. The Au NPs@SiO2-BODIPY solution with tetraethyl orthosilicate as silicon source was optimized in three aspects: the thickness of the silicon dioxide layer, the amount of BODIPY solution added, and the synthesis ratio of the catalyst EDC and NHS solution. The initial material addition ratio of the plasma enhanced fluorescent probe was V Au NPs :V TEOS =100:11, Based on this, the optimization experiment was carried out. First, the different TEOS addition amounts were optimized, and the other proportions remained unchanged. The fluorescence enhancement results showed that V Au NPs :V TEOS =50:3 has the best effect, so the second optimization uses V Au NPs :V TEOS =50:3 fixed ratio, and the amount of BODIPY solution added was optimized. The fluorescence enhancement results showed that The effect was the best. Then the third optimization continued to fix this ratio and optimized the ratio of catalyst EDC and NHS. The fluorescence enhancement results showed that The enhancement effect is the strongest. The synthetic data and enhancement multiples used are shown in Tables 1 and Figure 5 , from Table 1 and Figure 5 It can be seen that the maximum enhancement factor of Au NPs@SiO2-BODIPY solution with tetraethyl orthosilicate as the silicon source is 13.1, and the change of the thickness of the silicon dioxide layer has the greatest influence on the fluorescence enhancement factor, indicating that the shell thickness plays an important role in the plasma fluorescence enhancement effect. Au NPs :V TEOS=50:3, The subsequent instance detection was carried out under the conditions of , and finally the strongest fluorescence enhancement effect was achieved, which was 13 times.
[0102] Table 1 Synthesis parameters of Au NPs@SiO2-NH2 using tetraethyl orthosilicate as silicon source
[0103]
[0104]
[0105] Example 7
[0106] Fluorescence emission spectra of the BODIPY solution prepared in Example 1 and the plasmon-enhanced fluorescent probe Au NPs@SiO2-BODIPY solution.
[0107] According to the method of step (5) of Example 1, the Au NPs@SiO2-NH2 solution was replaced with ultrapure water to obtain a BODIPY solution of the same dilution concentration.
[0108] Fluorescence spectrum test: Test the fluorescence emission spectrum of the above solution. The fluorescence emission spectrum is scanned in the wavelength range of 490-600nm with an excitation wavelength of 480nm and a slit width of 5nm / 5nm for excitation and emission. The obtained fluorescence emission spectrum is shown in Figure 6 ,from Figure 6 It can be seen that the fluorescence intensity of Au NPs@SiO2-BODIPY solution (b) is much higher than that of BODIPY solution (a) with the same dilution concentration, and its enhancement factor is 13 times, indicating that Au NPs solution can enhance the fluorescence of BODIPY solution.
[0109] Example 8
[0110] The Au NPs solution, Au NPs@SiO2 solution, Au NPs@SiO2-NH2 solution, BODIPY solution and Au NPs@SiO2-BODIPY solution prepared in Example 1 were tested for Zeta potential.
[0111] The Zeta potential intensity of the above solution was measured using a Zeta potential and particle size analyzer. The resulting Zeta potential diagram is shown in Figure 7 , Figure 7The negative charge of the Au NPs solution is -26.44 mV (a); after Au NPs are coated with silica, the potential increases to -15.01 mV (b); when Au NPs@SiO2 is modified with amino groups, the potential further increases to -10.14 mV (c), indicating that the amino modification is successful; the fluorescent probe BODIPY itself is negatively charged with a potential of -15.08 mV (d); after grafting Au NPs@SiO2, the potential drops to -17.67 mV (e), indicating that Au NPs@SiO2-BODIPY is successfully synthesized.
[0112] Example 9
[0113] Infrared spectra of freeze-dried powders of the Au NPs solution, Au NPs@SiO2 solution, Au NPs@SiO2-NH2 solution, BODIPY solution and Au NPs@SiO2-BODIPY solution prepared in Example 1.
[0114] The above solution was placed in liquid nitrogen for quick freezing and freeze-dried using a freeze dryer. The freeze-dried powder material was detected using a Fourier transform infrared spectrometer (FT-IR). The infrared spectrum obtained is shown in Figure 8 , Figure 8 The Au NPs have carboxyl groups, so the -1 and 1728cm -1 There is an obvious peak at (a); after silica coating, 1074cm -1 and 457cm -1 The peak at 3425 cm-1 increased significantly, indicating that silica was successfully coated on Au NPs (b); -1 The peak at 1065 cm -1 and 457cm -1 The peak at 2919 cm-1 still exists, indicating that the amino group is successfully covered on the silica surface (c). The fluorescent probe BODIPY contains carboxyl groups, -1 and 1684cm -1 There is an obvious peak at 3343cm after BODIPY is grafted on Au NPs@SiO2-BODIPY (d). -1 and 1705cm -1 The peak at further increased, indicating that BODIPY modification was successful (e).
[0115] Example 10
[0116] Fluorescence lifetime diagram of transient fluorescence detection of the BODIPY solution prepared in Example 1 and the plasma fluorescence enhanced fluorescent probe Au NPs@SiO2-BODIPY solution.
[0117] The above solution was tested using a transient fluorescence spectrometer. The fluorescence lifetime diagram is shown in Fig. 9 , Fig. 9 The calculated fluorescence lifetime of BODIPY solution is 3.6ns (a), and that of Au NPs@SiO2-BODIPY solution is 3.3ns (b). The fluorescence lifetime of Au NPs@SiO2-BODIPY solution is shorter than that of BODIPY solution, indicating that BODIPY is successfully modified onto the surface of Au NPs@SiO2-NH2, and the strong electric field enhancement at the interparticle gap leads to the fluorescence enhancement effect.
[0118] Embodiment 11
[0119] Fluorescence intensity stability detection diagram of the plasma fluorescence enhanced fluorescent probe Au NPs@SiO2-BODIPY prepared in Example 1 at different pH values.
[0120] The plasmon fluorescence enhanced fluorescent probe Au NPs@SiO2-BODIPY prepared in Example 1 was placed in PBS buffers at different pH values (pH 6-10) and fluorescence detection was performed.
[0121] Fluorescence spectrum test: Test the fluorescence emission spectrum of the above solution. The fluorescence emission spectrum uses an excitation wavelength of 480nm, an excitation and emission slit width of 5nm / 5nm, and takes the ratio of the fluorescence intensity peak values of different solutions F / F0 to make a fluorescence response graph (F / F0, F0 is the original fluorescence intensity of the probe, and F is the fluorescence intensity of the probe as the pH changes). The obtained fluorescence spectrum is shown in Fig.10 ,from Fig.10 It can be seen that the plasma fluorescence enhanced fluorescent probe Au NPs@SiO2-BODIPY is stable to changes in the pH value of the surrounding environment.
[0122] Example 12
[0123] Fluorescence intensity stability detection diagram of the BODIPY solution prepared in Example 1 and the plasma fluorescence enhanced fluorescent probe Au NPs@SiO2-BODIPY at different times.
[0124] According to the method of step (5) of Example 1, the Au NPs@SiO2-NH2 solution was replaced with ultrapure water to obtain a BODIPY solution of the same dilution concentration. The plasma fluorescence enhanced fluorescent probe Au NPs@SiO2-BODIPY prepared in Example 1 and the BODIPY solution of the same dilution concentration were placed for a period of time (T = 0-9d) and fluorescence detection was performed.
[0125] Fluorescence spectrum test: Test the fluorescence emission spectrum of the above solution. The fluorescence emission spectrum is excitation wavelength 480nm, the slit width of excitation and emission is 5nm / 5nm, and the fluorescence intensity peak of different solutions is taken to make a fluorescence response graph. The obtained fluorescence spectrum is shown in Fig.11 ,from Fig.11 It can be seen that the fluorescence intensity of the plasma fluorescence enhanced fluorescent probe Au NPs@SiO2-BODIPY does not change significantly, and has a certain time stability (a); while the fluorescence intensity of the BODIPY solution with the same dilution concentration gradually decreases with the extension of the storage time, and has no time stability (b), indicating that the probe of the present invention is more stable after being modified by the Au NPs solution.
[0126] Example 13
[0127] Fluorescence changes of the BODIPY solution and the plasma fluorescence enhanced fluorescent probe Au NPs@SiO2-BODIPY prepared in Example 1 at different temperatures respectively with β-amyloid protein.
[0128] The BODIPY solution and the plasma fluorescence enhanced fluorescent probe Au NPs@SiO2-BODIPY prepared in Example 1 were mixed with β-amyloid protein and PBS buffer (pH=7.4) respectively, and incubated at different temperatures (25°C, 59°C) for 30 minutes before fluorescence detection. The final concentrations of the BODIPY solution and the plasma fluorescence enhanced fluorescent probe Au NPs@SiO2-BODIPY were both 90 μM, and the final concentration of β-amyloid protein was 20 μM.
[0129] Fluorescence spectrum test: Test the fluorescence emission spectrum of the above solution. The fluorescence emission spectrum is excitation wavelength 480nm, the slit width of excitation and emission is 5nm / 5nm, and the fluorescence intensity peak of different solutions is taken to make a fluorescence response graph. The obtained fluorescence spectrum is shown in Fig.12 ,from Fig.12 It can be seen that there is no obvious change in the fluorescence intensity of BODIPY solution and plasma fluorescence enhanced fluorescent probe Au NPs@SiO2-BODIPY after incubation alone (a); compared with incubation at 25°C (b), the fluorescence intensity of Au NPs@SiO2-BODIPY and β-amyloid protein after co-incubation at 59°C has a significant enhancement effect (c), indicating that β-amyloid protein can be completely aggregated at 59°C, and Au NPs@SiO2-BODIPY has a fluorescent response to β-amyloid protein and can be used to analyze β-amyloid protein.
[0130] Embodiment 14
[0131] Changes in fluorescence intensity and absorbance of the plasma fluorescence enhanced fluorescent probe Au NPs@SiO2-BODIPY prepared in Example 1 and β-amyloid protein at 59°C over time.
[0132] The plasma fluorescence enhanced fluorescent probe Au NPs@SiO2-BODIPY prepared in Example 1 was mixed with β-amyloid protein and PBS buffer, and incubated at 59°C for 0-30 min for fluorescence detection. The final concentration of the plasma fluorescence enhanced fluorescent probe Au NPs@SiO2-BODIPY was 90 μM, and the final concentration of β-amyloid protein was 20 μM.
[0133] Fluorescence spectrum test: Test the fluorescence emission spectrum of the above solution. The fluorescence emission spectrum uses an excitation wavelength of 480nm, an excitation and emission slit width of 5nm / 5nm, and takes the fluorescence intensity peaks of different solutions to make a fluorescence response graph.
[0134] UV-visible absorption spectrum test: Test the UV-visible absorption spectrum of the above solution. The UV-visible absorption spectrum uses pure water as the reference solution, and the absorption peaks of different solutions are taken to make absorbance response graphs.
[0135] The fluorescence emission spectrum of the fluorescent probe Au NPs@SiO2-BODIPY was enhanced by plasmon fluorescence ( Fig.13 Curve a) and UV-visible absorption spectrum ( Fig.13 Curve b) is combined to obtain the fluorescence intensity peak ratio F / F0-1 of different solutions to make a fluorescence response diagram. Fig.12 . Fig.12 It shows that after incubation at 59°C for 25 minutes, the ratio of the fluorescence intensity of β-amyloid protein almost reaches the peak value, and its turbidity gradually increases with protein aggregation. Therefore, the optimal incubation time for protein detection is about 25 minutes, at which time the protein has completely aggregated and the detection effect is also the best.
[0136] Embodiment 15
[0137] Linear fitting plot of the plasma fluorescence enhanced fluorescent probe Au NPs@SiO2-BODIPY prepared in Example 1 and β-amyloid protein.
[0138] The plasma fluorescence enhanced fluorescent probe Au NPs@SiO2-BODIPY prepared in Example 1 was mixed with β-amyloid protein and PBS buffer to prepare a solution with a β-amyloid protein concentration of 0-60 μM, and incubated at 59° C. for 30 min for fluorescence detection. The final concentration of the plasma fluorescence enhanced fluorescent probe Au NPs@SiO2-BODIPY was 90 μM.
[0139] Fluorescence spectrum test: Test the fluorescence emission spectrum of the above solution. The fluorescence emission spectrum is scanned in the wavelength range of 490-650nm with an excitation wavelength of 480nm and a slit width of 5nm / 5nm for excitation and emission. The fluorescence intensity peaks of different solutions are taken to make a fluorescence linear fitting graph. The obtained fluorescence spectrum is shown in Fig.14 , Fig.14 The fluorescence intensity of Au NPs@SiO2-BODIPY increased significantly with the increase of β-amyloid protein concentration, and the linear range of β-amyloid protein detection was 5-60 μM, with a detection limit of 0.85 μM. This indicates that the prepared probe can be used for the quantitative determination of β-amyloid protein.
[0140] Example 16
[0141] The fluorescence response diagram of the plasma fluorescence enhanced fluorescent probe Au NPs@SiO2-BODIPY prepared in Example 1 and other interferents.
[0142] The plasma fluorescence enhanced fluorescent probe Au NPs@SiO2-BODIPY was mixed with other interferents and PBS buffer and then subjected to fluorescence detection. The final concentration of the plasma fluorescence enhanced fluorescent probe Au NPs@SiO2-BODIPY was 90 μM, the final concentration of β-amyloid protein (Aβ) was 20 μM, the final concentration of acetylcholinesterase (AChE) was 100 U, and the final concentration of Na + The final concentrations of tyrosine (Tyr), D-proline (D-Pro), L-glutamic acid (L-Glu), D-glucose (D-GLU), D-threonine (D-Thr), L-tryptophan (L-Try), and cysteine (Cys) were all 20 μM.
[0143] Fluorescence spectrum test: Test the fluorescence emission spectrum of the above solution. The fluorescence emission spectrum is scanned with an excitation wavelength of 480nm, a slit width of 5nm / 5nm for excitation and emission, and a spectrum within the wavelength range of 490-650nm. The ratio of the fluorescence intensity peak values of different solutions is taken as F / F0-1 to make a fluorescence response diagram. Fig.15 . Fig.15 It shows that except for β-amyloid protein, other interfering substances have little fluorescence response to the probe, indicating that the prepared probe has good selectivity.
[0144] Embodiment 17
[0145] Cytotoxicity diagram of the BODIPY solution prepared in Example 1 and the plasma fluorescence enhanced fluorescent probe Au NPs@SiO2-BODIPY.
[0146] The BODIPY solution and the plasma fluorescence enhanced fluorescent probe Au NPs@SiO2-BODIPY prepared in Example 1 were diluted to different concentrations (0-10 μM) and added to CT26 cells pre-cultured for 24 h and incubated for 24 h. After washing twice with sterile PBS buffer, 10 μL of CCK-8 reagent was added and incubated for 2 h, and the absorbance at 450 nm was detected using a microplate reader.
[0147] The obtained cytotoxicity graph is shown in Fig.16 , Fig.16 The probe was shown to be almost nontoxic to CT26 cells in the range of 0-10 μM, indicating its good biocompatibility.
[0148] Embodiment 18
[0149] Intracellular laser confocal fluorescence imaging of the BODIPY solution prepared in Example 1 and the plasma fluorescence enhanced fluorescent probe Au NPs@SiO2-BODIPY.
[0150] The BODIPY solution (5 μM) and plasmon fluorescence enhanced fluorescent probe Au NPs@SiO2-BODIPY (5 μM) prepared in Example 1 were added to CT26 and PAN02 cells pre-cultured for 24 h, and thioflavin T (ThT) (5 μM) and β-amyloid protein (20 μM) were added and incubated for 4 h. The cells were then fixed with 4% paraformaldehyde for 5 min, washed twice with sterile PBS buffer, and incubated with Hoechst 33342 for 5 min. The cells were then detected using a Zeiss LSM710 laser confocal fluorescence microscope.
[0151] The laser confocal fluorescence imaging is shown in Fig.17 , Fig.17 Green fluorescence was shown on the surface of CT26 cells and PAN02 cells. At the same time, compared with BODIPY incubated with β-amyloid protein in CT26 cells and PAN02 cells, the fluorescence enhancement of Au NPs@SiO2-BODIPY on the cell surface was obvious. This also shows that Au NPs has a plasmon fluorescence enhancement effect on BODIPY, making the detection sensitivity of β-amyloid protein higher. Therefore, this probe has a good fluorescence enhancement effect and can be successfully applied to cell imaging to improve detection efficiency.
Claims
1. A method for preparing a fluorescent probe for plasma enhanced fluorescence, It is characterized in that The steps include: (1) 4-carboxybenzaldehyde, 2,4-dimethylpyrrole, trifluoroacetic acid, tetrachlorobenzoquinone, triethylamine, and boron trifluoride etherate are mixed and reacted to prepare the fluorescent probe BODIPY; (2) adding sodium citrate to a chloroauric acid solution to react and prepare a gold nanoparticle solution; (3) reacting an organic solvent, ammonia water and tetraethyl orthosilicate in the gold nanoparticle solution to obtain a gold nanoparticle solution coated with silicon dioxide; (4) reacting (3-aminopropyl)trimethoxysilane with a solution of gold nanoparticles coated with silica to obtain an amino-modified solution of silicon-coated gold nanoparticles; (5) Plasmon-enhanced fluorescent probe Au NPs@SiO was prepared by reacting BODIPY fluorescent probe, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N-hydroxysuccinimide and amino-modified silicon-coated gold nanoparticle solution. 2 -BODIPY.
2. The preparation method according to claim 1, It is characterized in that In step (1), 4-carboxybenzaldehyde is dissolved in dichloromethane, and then 2,4-dimethylpyrrole is added and trifluoroacetic acid is added dropwise to the mixed solution, and stirred at room temperature for 10-14 hours; then tetrachlorobenzoquinone is added and reacted at room temperature for 4-6 hours, and then triethylamine is added and reacted at room temperature for 20-40 minutes, and finally boron trifluoride etherate is added and stirred at room temperature overnight. The product is purified by chromatography on a silica gel column to obtain a solid powder of the fluorescent probe BODIPY.
3. The preparation method according to claim 1, It is characterized in that In step (1), the molar ratio of 4-carboxybenzaldehyde, 2,4-dimethylpyrrole and tetrachlorobenzoquinone is 1-2:2-4:1-2; the volume ratio of dichloromethane, triethylamine and boron trifluoride etherate is 3-12:1:1; and the amount of trifluoroacetic acid added is 1-4 drops.
4. The preparation method according to claim 1, It is characterized in that In step (2), the chloroauric acid aqueous solution is heated to boiling, and then the sodium citrate solution is added to react, and the solution is allowed to turn into wine red and then continued to boil for 3-7 minutes. After the solution is cooled, a gold nanoparticle solution is obtained; in step (2), the mass ratio of chloroauric acid to sodium citrate is 1:1-10.
5. The preparation method according to claim 1, It is characterized in that In step (3), an organic solvent and aqueous ammonia are added to the gold nanoparticle solution, and then an ethyl orthosilicate solution is added to continue reacting at room temperature for 6-24 hours to obtain a gold nanoparticle solution coated with silica; in step (3), the volume ratio of the gold nanoparticle solution, the organic solvent, aqueous ammonia, and ethyl orthosilicate is 100:100-300:3-10:4-12.
6. The preparation method according to claim 1, It is characterized in that In step (4), (3-aminopropyl)trimethoxysilane and the silicon-coated gold nanoparticle solution are reacted at 30-40° C. for 3-7 hours, and then reacted at 40-60° C. for 1-2 hours to obtain an amino-modified silicon-coated gold nanoparticle solution; in step (4), the volume ratio of (3-aminopropyl)trimethoxysilane to the silicon-coated gold nanoparticle solution is 1-3:
10.
7. The preparation method according to claim 1, It is characterized in that In step (5), the BODIPY solution and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride are mixed and stirred at room temperature for 5-15 minutes, and then N-hydroxysuccinimide is added to the mixed solution and stirred at room temperature for 10-30 minutes, and finally the amino-modified silicon-coated gold nanoparticle solution is added and stirred at room temperature for 3-5 hours to obtain the plasmon-enhanced fluorescent probe Au NPs@SiO 2 -BODIPY.
8. The preparation method according to claim 1, It is characterized in that In step (5), the molar ratio of BODIPY solution, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N-hydroxysuccinimide, and amino-modified silicon-coated gold nanoparticle solution is preferably 0.2-1:300-900:300-900:
1.
9. A fluorescent probe of plasmon enhanced fluorescence prepared by the preparation method according to claim 1.
10. Use of the fluorescent probe prepared by the preparation method according to claim 1 in detecting β-amyloid protein and living cell fluorescence imaging.
